Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets firm up
Thu, 6 Mar 01:30 pm

Indian share markets soared higher in the post-noon trading session. Barring FMCG, all the sectoral indices are trading in the green with realty, power and metal stocks being the biggest gainers.

BSE-Sensex is up 124 points and NSE-Nifty is trading 44 points up. BSE Mid Cap is trading 1.3% up and BSE Small Cap index is trading up by 1.4%. The rupee is trading at 61.2 to the US dollar.

Most of the auto ancillary stocks are trading in the green with Wheels India and Bharat Forge being the biggest gainers. As per a leading financial daily, Bharat Forge has been de-risking its business over the last five years by increasingly selling forged products to non-automotive sectors such as oil & gas, power, railways, defence, mining and construction. The share of its domestic revenues from the non-automotive segment has risen from 28% in FY09 to 39% in FY13. Bharat Forge wants to raise the share of non-auto sales to 60% in two years. Several of the company's diversification ventures are in partnerships. In defence, the company has a joint venture with Israel based company Elbit Systems and an alliance with defence and security company Saab. Even in energy, Bharat Forge has a joint venture with French major Alstom. Bharat Forge's stock is presently trading up 3.6%.

Majority of the pharma stocks are trading in the green with J B Chemicals and Elder Pharma being among major gainers whereas Lupin and Ipca Labs are a few stocks trading in the red. As per a leading financial daily, Swedish company Sanofi has slapped a patent infringement case against Glenmark on cardiac drug Multaq in Delaware. Sanofi has filed a suit against both Glenamrk and Dublin based Actavis (Watson) to restrain them from commercializing their Abbreviated New Drug Application (ANDA) products before the expiry of certain US patents. Multaq drug is indicated to reduce the risk of hospitalization for atrial fibrillation and had total sales of $ 319 m in 2013 as per IMS Health data. Glenmark's stock is currently trading up by 0.7%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets firm up". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.